Core Insights - The survey indicates strong global support for smoke-free alternatives to cigarettes, with 78% of respondents agreeing that adult smokers should have access to better options [2][3] - There is significant concern (76%) that public health decisions are influenced more by ideology than by scientific evidence [3][6] - Countries that adopt smoke-free products have experienced declines in cigarette sales and smoking rates, highlighting the demand for evidence-based policies [4] Group 1: Public Support for Smoke-Free Alternatives - 80% of adults believe that smokers should have access to smoke-free options [1] - 74% of respondents think that encouraging smokers to switch to these products can improve public health [2] - 78% of respondents want their governments to consider scientific evidence regarding smoke-free alternatives before imposing restrictions [3] Group 2: Concerns Over Public Health Policies - 76% of respondents are concerned that decisions are made based on ideology rather than science [3][6] - 58% agree that it is wrong for governments to ban less harmful alternatives while allowing cigarette sales [6] - 61% believe it is a public health failure that 29% of the global adult population lives in countries where smoke-free alternatives are banned [6] Group 3: Market Access and Regulatory Environment - Over 190 million smokers in more than 20 countries lack legal access to smoke-free products, despite the availability of harmful cigarettes [5] - 82% of legal-age smokers in countries with bans on smoke-free products want the opportunity to purchase them legally [6] - The survey highlights a strong desire for governments to adopt policies that align with scientific findings, particularly in countries with existing bans [3][6] Group 4: Company Position and Investment - Philip Morris International has invested over $14 billion since 2008 in developing smoke-free products, aiming to end cigarette sales [8] - As of June 30, 2025, smoke-free products accounted for 41% of PMI's total net revenues [8] - PMI's smoke-free products are available in 97 markets, with over 41 million legal-age consumers using them [8]

Industry Overview - The Zacks Tobacco industry is shifting towards smoke-free alternatives due to increased consumer health awareness and stricter regulations on traditional cigarettes [1][4] - Major companies like Philip Morris International, Altria Group, and Turning Point Brands are investing in reduced-risk products (RRPs) to cater to the demand for healthier nicotine options [1][4] Market Trends - The popularity of smoke-free options, such as heated tobacco and vaping products, is reshaping the industry as consumers seek safer alternatives [4] - Tobacco companies are leveraging strong pricing power to maintain revenues despite declining cigarette sales, as loyal consumers tend to absorb price increases [2][5] Challenges - The industry faces challenges in cigarette sales volumes due to inflation and changing consumer behavior, alongside regulatory restrictions impacting sales and advertising [6] Industry Performance - The Zacks Tobacco industry ranks 65, placing it in the top 27% of over 250 Zacks industries, indicating positive near-term prospects [7][8] - The industry has outperformed the broader market, gaining 63.8% over the past year compared to the S&P 500's 9.8% increase [10] Valuation - The industry is currently trading at a forward P/E of 15.78X, lower than the S&P 500's 21.89X and the sector's 17.62X [13] Company Highlights - **Altria Group**: Focused on transitioning to a smoke-free future with its oral nicotine pouch brand, on!, and has seen a 29.3% increase in shares over the past year [15][17] - **Philip Morris International**: Leading in RRPs with products like IQOS and ZYN, shares have surged 81% in the past year [20][21] - **Turning Point Brands**: Gaining traction with innovative products and strong demand for smokeless alternatives, shares have skyrocketed 132.8% in the past year [24][25]

Core Insights - Altria Group, Inc. is experiencing significant challenges in its smokeable products segment, with a notable decline in cigarette volumes and revenues [1][8] - The overall tobacco industry is facing economic pressures, leading to a shift towards discount brands and an increase in illicit e-vapor products [2][3] Company Performance - In Q1 2025, Altria's domestic cigarette shipment volumes decreased by 13.7%, while net revenues from the smokeable segment fell by 5.8% year over year to $4.62 billion [1][8] - The company's total revenues dropped by 5.7% in the same quarter, reflecting the impact of economic strain on consumers [2] Market Dynamics - Inflation and stagnant wage growth are pushing low-income smokers towards cheaper alternatives, resulting in a 1.8 share point gain for the discount cigarette segment [2] - Altria's flagship Marlboro brand experienced a 1-point decline in retail share year over year [2] Competitive Landscape - The illegal disposable e-vapor market is estimated to dominate over 60% of the e-vapor market, further impacting traditional cigarette demand [3] - Competitors like Philip Morris International and British American Tobacco are also facing structural pressures in their combustible segments, with both companies pivoting towards reduced-risk products (RRPs) [5][6] Strategic Response - Altria may need to accelerate its transition to smoke-free alternatives to sustain growth and investor confidence, as evidenced by its investments in platforms like NJOY and on! [4] - The company’s current valuation shows a forward price-to-earnings ratio of 10.73X, below the industry average of 15.47X, indicating potential undervaluation [10] Earnings Estimates - The Zacks Consensus Estimate for Altria's 2025 earnings implies a year-over-year growth of 5.3%, with a 3% uptick expected in 2026 [12]